You are in: eMedicine Specialties > Dermatology > BACTERIAL INFECTIONS Gram-Negative Toe Web InfectionArticle Last Updated: May 12, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Medicine, Professor of Pediatrics, Professor of Pathology, Professor of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School Robert A Schwartz is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi Coauthor(s): Jarrett R Hesselbirg, New Jersey Medical School Editors: Takeji Nishikawa, MD, Emeritus Professor, Department of Dermatology, Keio University School of Medicine; Director, Samoncho Dermatology Clinic; Managing Director, The Waksman Foundation of Japan Inc; David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic; Rosalie Elenitsas, MD, Associate Professor of Dermatology, University of Pennsylvania School of Medicine; Director, Penn Cutaneous Pathology Services, Department of Dermatology, University of Pennsylvania Health System; Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University; William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System Author and Editor Disclosure Synonyms and related keywords: gram-negative bacillary interdigital infection, gram-negative foot impetigo, bacterial infections of the foot, interweb foot infection, interweb foot impetigo, interdigital foot infection, interdigital infection, bacterial toe web infection, Pseudomonas aeruginosa, P aeruginosa, Moraxella species, Alcaligenes species, Acinetobacter species, Proteus species, Erwinia species, tinea pedis INTRODUCTIONBackgroundGram-negative interweb foot impetigo is a relatively common and troubling disorder.1 The infection is commonly associated with the use of closed-toe or tight-fitting shoes and in individuals in whom strong physical exertion plays an important role in athletic, occupational, or recreational activities. Gram-negative mixed bacterial infection with organisms, such as Moraxella, Alcaligenes, Acinetobacter, Pseudomonas, Proteus, and Erwinia species, may represent a mild secondary infection of tinea pedis. Over time, in the setting of moisture and maceration, multiple fungal and bacterial organisms may proliferate.2 The process may progress to advanced stages of gram-negative infection with sepsis.
PathophysiologyTypically, the interweb space is colonized by polymicrobial flora. Initially, a dermatophyte infection at this site may damage the stratum corneum and produce natural substances with antibiotic properties that alter the composition of the resident bacterial flora, encouraging the proliferation of antibiotic-resistant strains.3 Gram-negative bacteria may resist the antibacterial agents and many of the commonly used therapeutic agents. In other cases, marked hyperhidrosis with cutaneous maceration, often seen in people who enjoy vigorous athletic endeavors, may predispose individuals to gram-negative bacterial toe web infection. Pseudomonas aeruginosa, often together with other gram-negative bacteria, is the most common etiologic agent.1 The toe web space provides a hospitable niche for gram-negative microorganisms; infection can quickly progress from mild overgrowth of resident bacteria to an advanced, severe, gram-negative infection. Lesions that affect the interdigital spaces can occasionally extend to the planta and the backs of the toes. The most frequent complaint of patients is burning and pain, and, in severe infection, problems with walking are noted. Gram-negative bacteria gain access to the bloodstream from foci of tissue infection or possibly from heavy colonization. Trauma, tinea pedis, or depressed host resistance, as in diabetes mellitus or HIV disease, may also predispose individuals to the infection. FrequencyUnited StatesFew data are available on the frequency of gram-negative toe web infections. InternationalA limited number of cases have been reported. Mortality/MorbidityThis disorder can rarely progress to a life-threatening situation. Occasionally, in advanced severe cases, certain microorganisms (eg, P aeruginosa) can cause therapeutic problems in relation to antibiotic resistance and a risk of potential lethal complications. If septicemia occurs, especially in a patient who is immunocompromised, the condition may produce shock and death. Acute bacterial cellulitis is a potentially serious, often recurrent infection. Risk factors for acute bacterial cellulitis in hospitalized patients were found to include the presence of sites of pathogen entry on toe webs.4 Improved awareness and management of toe web intertrigo, which may harbor bacterial pathogens, may reduce the prevalence of cellulitis.5 RaceGram-negative toe web infection can affect any race. SexMen appear to be more frequently affected, with a male-to-female ratio of 4:1 reported in one study.1 AgeGram-negative toe web infection affects young and elderly persons. In one series, patients were reported to be aged 1-74 years. The disorder rarely involves infants or children. CLINICALHistoryThe patient usually complains of a burning sensation between the toes, often with maceration. A malodorous exudate may be evident.
PhysicalClinical manifestations are similar for most patients.
CausesThe cause of gram-negative toe web infections may be related to several factors.
DIFFERENTIALSCandidiasis, Cutaneous Erythrasma Hyperhidrosis Intertrigo Tinea Pedis
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Econazole nitrate cream (Spectazole) |
|---|---|
| Description | Antifungal agent that is a water-miscible base consisting of pegoxol 7 stearate, peglicol 5 oleate, mineral oil, benzoic acid, butylated hydroxyanisole, and purified water. The color of the soft cream is white to off white, and it is for topical use only. Exhibits broad-spectrum activity against many gram-negative organisms. Econazole nitrate cream 1% is supplied in tubes of 15 g, 30 g, and 85 g. |
| Adult Dose | Apply sparingly to cover affected areas qd in patients with tinea pedis, tinea cruris, tinea corporis, and tinea versicolor Apply bid (morning and evening) in patients with cutaneous candidiasis |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Discontinue if sensitivity or irritation develops; for external use only; avoid contact with eyes |
Therapy must cover all likely pathogens in the context of the clinical setting.
| Drug Name | Cefoperazone (Cefobid) |
|---|---|
| Description | For treatment of skin and skin structure infections. Active against a wide range of aerobic and anaerobic, gram-positive, and gram-negative pathogens. Bactericidal action results from inhibition of bacterial cell wall synthesis. Has a high degree of stability in the presence of beta-lactamases produced by most gram-negative pathogens. Can be administered by injection or intravenously. |
| Adult Dose | 2-4 g/d IV/IM divided bid; not to exceed 12 g/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Increases effects of anticoagulants; disulfiram reactions may occur with alcohol (within 72 h of intake); probenecid may prolong effects; concurrent administration with aminoglycosides or furosemide may increase risk of nephrotoxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in severe renal or hepatic impairment; prolonged use may result in superinfection; may reduce vitamin K–producing intestinal bacteria and interfere with hemostasis |
| Drug Name | Cefotaxime sodium (Claforan) |
|---|---|
| Description | Third-generation semisynthetic broad-based antibiotic with gram-negative spectrum. Lower efficacy against gram-positive organisms. Specimens for bacteriologic culture should be obtained prior to therapy to test for susceptibilities to cefotaxime sodium. |
| Adult Dose | 500 mg or 1 g IM; not to exceed 12 g/d |
| Pediatric Dose | <50 kg: 50-180 mg/kg IV/IM divided into 4-6 equal doses >50 kg: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase levels; coadministration with furosemide and aminoglycosides may increase nephrotoxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy; has been associated with severe colitis; caution in history of gastrointestinal tract disease, particularly colitis |
| Drug Name | Ciprofloxacin (Cipro) |
|---|---|
| Description | Synthetic broad-spectrum antimicrobial agent that inhibits bacterial DNA synthesis and, consequently, growth. Film-coated tab is available in 100 mg, 250 mg, 500 mg, and 750 mg. Oral susp is white to slightly yellow with a strawberry flavor and may contain yellow-orange droplets. Tablets are well absorbed in gastrointestinal tract after oral administration. Has a wide range of activity against gram-negative organisms. |
| Adult Dose | 500 mg PO q12h |
| Pediatric Dose | <18 years: Not recommended >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Antacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; reduces therapeutic effects of phenytoin; probenecid may increase serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy |
| Drug Name | Gentamicin sulfate (G-Myticin, Jenamicin, Garamycin) |
|---|---|
| Description | Wide-spectrum antibiotic that provides highly effective topical treatment in primary and secondary bacterial infections of the skin. Gentamicin sulfate may clear infections that have not responded to other topical antibiotic agents. Treats superinfections caused by fungi or viruses. Treats skin and skin structure infections. Usual duration of treatment is 7-10 d. In more serious infections, longer course of therapy is needed. Patients should be well hydrated during treatment. May also be used parenterally as a water-soluble injection against a wide variety of pathogenic bacteria. May be considered as initial therapy in suggested or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. |
| Adult Dose | Topical: Apply sparingly to lesions tid/qid; area may be covered with gauze dressing Parenteral: 3 mg/kg/d IV divided tid/qid; reduce dose to 1.25 mg/kg/d for maintenance as soon as clinically indicated; can eventually be reduced to 1.15 mg/kg/d IV q8h |
| Pediatric Dose | Topical Apply as in adults Parenteral <5 years: 2.5 mg/kg/dose IV/IM q8h >5 years: 1.5-2.5 mg/kg/dose IV/IM q8h or 6-7.5 mg/kg/d divided q8h; not to exceed 300 mg/d; monitor as in adults |
| Contraindications | Documented hypersensitivity; non–dialysis-dependent renal insufficiency if administered parenterally |
| Interactions | None reported for topical formulation; coadministration of parenteral formulation with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; because aminoglycosides enhance effects of neuromuscular-blocking agents, prolonged respiratory depression may occur; coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (monitor regularly) |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Pregnancy category D if administered parenterally; topical antibiotics occasionally allow overgrowth of nonsusceptible organisms, including fungi (discontinue treatment if overgrowth occurs or if irritation or sensitization develops); adverse reactions include irritation, erythema, and pruritus; parenteral formulation has narrow therapeutic index (not intended for long-term therapy); caution in renal failure (patients not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment |
| Drug Name | Castellani paint |
|---|---|
| Description | Castellani paint acquired its name from an Italian physician, Sir Aldo Castellani (1877-1971); it is also called carbolfuchsin paint. Is a fungicidal and bactericidal liquid with an anesthetic effect on the skin and an antiseptic and drying agent. Is a magenta liquid that stains the skin red. The paint mixture is composed of resorcinol (8 g), acetone (4 mL), magenta (0.4 g), phenol (4.0 g), boric acid (0.8 g), industrial methylated spirit 90% (8.5 mL), and water (100 mL). Can be prepared in colorless form. |
| Adult Dose | Apply daily for 2 wk usually qhs |
| Pediatric Dose | <10 years: Do not administer >10 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Phenols may cross react with resorcin, cresols, and hydroquinone |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Guard against spilling; can stain clothing and skin; may be toxic in children because of phenol content; may cause irritation, especially in diaper or other intertriginous regions; may be toxic in dilute solutions if used over large areas |
The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Dr. Frantisek Vosmik, to the development and writing of this article.
| Media file 1: A 33-year-old man with interweb exudative patches. Courtesy of Rajendra Kapila, MD, Professor of Infectious Diseases, New Jersey Medical School. | |
![]() | View Full Size Image | Media type: Photo |
Gram-Negative Toe Web Infection excerpt
Article Last Updated: May 12, 2008